Compass Therapeutics, Inc. (NASDAQ:CMPX) Director Sells $5,678,570.52 in Stock

Compass Therapeutics, Inc. (NASDAQ:CMPX) Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total value of $5,678,570.52. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Compass Therapeutics Trading Up 2.7 %

CMPX stock opened at $1.70 on Friday. The business’s 50-day moving average is $2.56 and its 200 day moving average is $2.10. Compass Therapeutics, Inc. has a 12-month low of $0.77 and a 12-month high of $4.08. The stock has a market cap of $234.39 million, a price-to-earnings ratio of -4.58 and a beta of 1.40.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, equities analysts forecast that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.

Institutional Trading of Compass Therapeutics

A number of hedge funds have recently bought and sold shares of CMPX. Squarepoint Ops LLC purchased a new stake in shares of Compass Therapeutics in the fourth quarter valued at approximately $35,000. Tang Capital Management LLC increased its stake in shares of Compass Therapeutics by 225.4% in the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after acquiring an additional 4,087,005 shares during the last quarter. ProShare Advisors LLC raised its holdings in shares of Compass Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock worth $42,000 after acquiring an additional 9,451 shares during the period. MPM Bioimpact LLC raised its holdings in shares of Compass Therapeutics by 51.9% during the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock worth $12,423,000 after acquiring an additional 2,926,002 shares during the period. Finally, Enavate Sciences GP LLC purchased a new stake in shares of Compass Therapeutics in the fourth quarter valued at about $11,293,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Wall Street Analyst Weigh In

CMPX has been the subject of several recent research reports. Piper Sandler initiated coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price target for the company. Wedbush reaffirmed an “outperform” rating and set a $8.00 target price on shares of Compass Therapeutics in a report on Tuesday, April 1st. Guggenheim reissued a “buy” rating and set a $12.00 price target on shares of Compass Therapeutics in a report on Wednesday, April 2nd. Jefferies Financial Group lifted their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday, February 10th. Finally, Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 1st. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Compass Therapeutics presently has an average rating of “Buy” and an average price target of $13.38.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.